| Objective:By comparing the therapeutic effects(recent and long-term outcomes)between recombinant human endostatin and chemotherapy in advanced non-small cell lung cancer,explore the therapeutic advantages of vascular targeted therapy and provide optimal treatment for advanced non-small cell lung cancer Clinical basis.Methods:In this study,122 cases of locally advanced or recurrent metastatic NSCLC diagnosed by histopathology and/or cytology were included.The above cases were divided into the recombinant human endostatin(Endo)combined chemotherapy group(Endo group).In both the chemotherapy and chemotherapy groups,both groups were applied to disease progression or intolerable side effects.Calculate the two groups of long-term and long-term curative effects,and perform intragroup and subgroup analysis according to the parameters to study the effect of various factors on the curative effect.Finally,the toxicities and side effects of different treatment regimens were evaluated according to the grading criteria of WHO-related toxicities and side effects.SPSS 21.0 software was used to analyze the counting data by chi-square test.Survival curves were drawn by Kaplan-Meier method.PFS and OS were compared by Log-Rank test.Using COX Regression Analysis to Evaluate the Impact of Clinical Parameters on Survival.P<0.05 was considered as statistically significant.Results:1.General characteristics of patients: In addition to statistical differences in age(P=0.044),122 patients had better balance in other parameters(P>0.05).2.Therapeutic effect: There was no significant difference in ORR and DCR between the patients in the Endo group and the chemotherapy group.By stratifying the two groups of patients,it was concluded that the ORR of the ECOG PS score equal to 1 was significantly higher in the Endo group(15%)than in the chemotherapy group(5%),with a statistically significant difference(P=0.048).3.Survival analysis: The median overall PFS for the Endo group and the chemotherapy group was 6.4 months and 5.4 months respectively,with a statistically significant difference(P=0.02).The median PFS of the first-line groups was 6.6 months and 6.4 months,respectively,and the difference was statistically significant(P=0.045).The median OS of the Endo group and the chemotherapy group was 14.9 months and 10.9 months,respectively,with statistically significant differences(P=0.0008).The median OS in the first-line patients was 15.0 months and 13.3 months,respectively.There was a statistically significant difference(P=0.004).The OS of the two groups above the second line was 10.1 months and 6.3 months respectively,and the difference was statistically significant(P=0.004).ECOG PS scores can affect patients with PFS(P=0.003),and patients with PS scores of 0-1 can significantly reduce the risk of disease progression.4.Adverse events: the main adverse reactions in group 2 were leukopenia,anemia,nausea,vomiting,neurotoxicity,all with grade II and below,and all adverse reactions between the two groups had no significant difference.Conclusions:1.On the basis of standard chemotherapy,combined with Endo treatment can significantly increase the short-term efficacy,improve the long-term survival of patients,showing obvious advantages over chemotherapy alone,and does not increase the incidence of adverse chemotherapy.2.The therapeutic advantage of combination therapy was more obvious in patients with an ECOG PS score of 1 and significantly improved the treatment effect compared with standard chemotherapy.3.The ECOG score was the median PFS influence factor.Patients with PS equal to 2 had a 4.59-fold increased risk of disease progression compared with 0-1 patients with PS. |
PDF Full Text Request